Source - RNS
RNS Number : 8864M
Immunodiagnostic Systems Hldgs PLC
19 October 2016


Immunodiagnostic Systems Holdings plc.

19 October 2016


Launch of IDS-iSYS Total Testosterone assay - new assay in the IDS fertility portfolio


Immunodiagnostic Systems Holdings plc (IDS), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, has launched the IDS-iSYS Total Testosterone assay in the European market. This is a fully automated CLIA assay for use with serum and plasma samples on the IDS-iSYS Automated System.


The launch of the IDS-iSYS Total Testosterone assay is the second product released as part of the emerging fertility (steroid hormones) portfolio following the launch of the IDS-iSYS 17-OH Progesterone assay in May 2016. 

The IDS-iSYS Total Testosterone assay quantitatively measures a patient's Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens).

The global market for testosterone tests has been valued at around $110 million per year.


For further information:


Immunodiagnostic Systems Holdings plc                   Tel: +44 (0) 191 519 0660

Patricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director


Peel Hunt LLP                                                              Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson


This information is provided by RNS
The company news service from the London Stock Exchange